Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.79 |
| ▸ | THRB | P10828 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.79 |
| ▸ | RECQL | P46063 | 6/20 | 0.79 |
| ▸ | BLM | P54132 | 6/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.79 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | TOP2A | P11388 | 4/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | STAT6 | P42226 | 4/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.79 |
| ▸ | HTT | P42858 | 3/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675027 | 1.00 | MEN1 (0.79) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL17929839 | 0.96 | MEN1 (0.78) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL15682452 | 0.96 | MEN1 (0.78) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL14524965 | 0.96 | MEN1 (0.78) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL14867452 | 0.96 | MEN1 (0.84) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL31237938 | 0.94 | MEN1 (0.77) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL10138466 | 0.94 | MEN1 (0.81) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL16015696 | 0.93 | MEN1 (0.80) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL26387964 | 0.93 | MEN1 (0.80) | MEN1THRBKMT2ARECQLBLM | |
| SCHEMBL12462937 | 0.93 | MEN1 (0.80) | MEN1THRBKMT2ARECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| US-20100113328-A1 | Targeted delivery to legumain-expressing cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113328-A1 | Targeted delivery to legumain-expressing cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-06 | — | — | US | disclosed |
| US-7608591-B2 | Prodrug comprising cytosine arabinoside or doxorubicin linked to legumain peptide substrate having peptide consisting of amino acid sequence Ala-Ala-Asn-Leu where legumain cleaves peptide at link between Asn and other amino acid to generate active cytosine arabinoside or doxorubicin from prodrug; cancer | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113328-A1 | Targeted delivery to legumain-expressing cells | LGMN, ENGASE, MMEL1 | MEN1 901/4885THRB 4022/4885KMT2A 4067/4885 |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | MEN1 2733/4885THRB 3917/4885KMT2A 3581/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | MEN1 2733/4885THRB 3917/4885KMT2A 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.